Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

[1]  Laura Catarina Gomes Nunes.  Relatórios de Estágio realizado na Farmácia Ferreira de Sousa e na Fondazione IRCCS Istituto Nazionale dei Tumori , 2019 .

[2]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[3]  A. Chella,et al.  Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial , 2019, Clinical Cancer Research.

[4]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. V. Van Schil,et al.  Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  L. Strigari,et al.  A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab , 2019, Journal of Translational Medicine.

[7]  F. Cappuzzo,et al.  Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. , 2018, European journal of cancer.

[8]  S. Leschka,et al.  Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) , 2018, Cancer Immunology, Immunotherapy.

[9]  E. Vasile,et al.  Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Jie Tian,et al.  PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model , 2018, BMC Cancer.

[11]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[12]  K. O'Byrne,et al.  Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. , 2018 .

[13]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  Hidekazu Suzuki,et al.  Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial , 2018, PloS one.

[15]  A. Scherpereel,et al.  Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. , 2018, Lung cancer.

[16]  M. Milano,et al.  Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. , 2017, Journal of thoracic disease.

[17]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[18]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[19]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[20]  Ping Yang,et al.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.

[21]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[22]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[23]  E. Vasile,et al.  Natural History of Non-Small-Cell Lung Cancer with Bone Metastases , 2015, Scientific Reports.

[24]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[25]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[26]  K. Hemminki,et al.  Metastatic sites and survival in lung cancer. , 2014, Lung cancer.

[27]  M. Clemons,et al.  Incidence and consequences of bone metastases in lung cancer patients , 2013, Journal of bone oncology.

[28]  Huanbin Xu,et al.  Bone marrow and the control of immunity , 2011, Cellular and Molecular Immunology.

[29]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[30]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[31]  S. Peters,et al.  OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 , 2017 .

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.